Improve the lives of patients suffering from Alzheimer

13 Jun 2017

Preclinical studies on the disease-modifying effect of NP03 in AD have been conducted in McGill University, Montreal CA. NP03 is a disease modifying drug and induced neurogenesis. A phase II is planned for the treatment of psychosis associated with AD.